Incretin Effect in Patients With Psoriasis and Controls

Psoriasis Vulgaris Clinical Trial

Official title:

Incretin Effect in Patients With Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06064084
• Other study ID #: 11031999
• Status: Completed
• Start date: September 11, 2011
• Est. completion date: September 11, 2015

Study information

• Verified date: September 2023
• Source: University Hospital, Gentofte, Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To investigate the incretin effect and postprandial incretin responses in plasma in patients with psoriasis

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: September 11, 2015
• Est. primary completion date: September 11, 2015
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

no diabetes BMI < 27 kg/m^2 normal Glucose tolerance test at screening normal fasting plasma glucose no islet auto antibodies no hormonel contraception informed consent psoriasis vulgaris (PASI>8) (case not controls) Exclusion Criteria: other chronic inflammtory skin disease other chronic inflammatory disease pregnancy psychiatric illness

Related Conditions & MeSH terms

• Psoriasis
• Psoriasis Vulgaris

Intervention

Diagnostic Test:
• Oral glucose tolerance test
Oral glucose tolerance test 50g

Other:
• Intravenous isoglycaemic glucose clamp
Intravenous isoglycaemic glucose clamp
• Liquid Mixed meal test
Liquid Mixed meal test 520 kcal

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Gentofte, Copenhagen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incretin effect measured with Beta-cell secretory response	Incretineffect (%) = 100 % × (Beta-cell Secretory Response (OGTT) - Beta-cell Secretory Response (IIGI)) / Beta-cell Secretory Response (OGTT)	0-180 minutes
Secondary	Insulin sensitivity measures	Matsudas insulin sensitivity index: (10,000 / vglucose minute 0 x insulin minute 0) (mean glucose (OGTT) x mean insulin OGTT))	0-180 minutes
Secondary	Concentration of Glucose-independent insulinotropic polypeptide	Evaluted as Area Under the Curve	0-180 minutes
Secondary	Concentration of Glucagon-like peptide 1	Evaluated as Area Under the Curve	0-180 minuntes
Secondary	Concentration of Glucagon	Evaluated as Area Under the Curve	0-180 minutes
Secondary	Concentration of Insulin	Evaluated as Area Under the Curve	0-180 minutes